Printable Medicines: A Microdosing Device For Producing Personalized Medicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Printable Medicines: A Microdosing Device For Producing Personalized Medicines
The authors describe a new method for the production of personalised medicines involving the direct printing of drug solutions or suspensions containing APIs and excipients onto edible paper carrier materials utilising ultra-precise microdrop printing technology. The approach allows ultra-precise dosing of the API according to the specific requirements of each individual patient and is suited for highly active low-dose drugs.


Pharmaceutical Technology Europe
Volume 23, Issue 1

Conclusions


The authors say...
We present a method for manufacturing a medication using microdrop printing technology, which offers new possibilities in the fields of personalised medicine, the production of lowdosage forms, including process verification, documentation and labelling, and the individual adjustment of the medication with respect to multidosing and controlled drug release. The system has already been extensively tested, provides an innovative mechanism to prevent counterfeit medications and seems to be suitable for the formulation of highly potent and active drug substances.

Christine Voura is Senior Researcher from the Research Center Pharmaceutical Engineering GmbH, Graz, Austria.

Michael M. Gruber is Junior Researcher from the Research Center Pharmaceutical Engineering GmbH, Graz, Austria.

Nina Schroedl is Technician from the Research Center Pharmaceutical Engineering GmbH, Graz, Austria.

Daniela Strohmeier is Technician from the Research Center Pharmaceutical Engineering GmbH, Graz, Austria.

Bernhard Eitzinger is R&D Manager from Dr. Franz Feurstein GmbH, Traun, Austria.

Wolfgang Bauer is Professor from the Institute for Paper, Pulp and Fibre Technology, Graz University of Technology, Graz, Austria.

Guenter Brenn is Professor from the Institute of Fluid Mechanics and Heat Transfer, Graz University of Technology, Graz, Austria.

Johannes G. Khinast is Professor from the Research Center Pharmaceutical Engineering GmbH, Graz/Austria and the Institute for Process and Particle Engineering, Graz University of Technology, Graz, Austria.

Andreas Zimmer is the article's corresponding author and Professor from the the Institute of Pharmaceutical Sciences, Karl-Franzens University of Graz, Graz, Austria.
Tel. +43 316 380 8880

References

1. W.E. Katstra et al., Journal of Controlled Release, 66(1), 1–9 (2000).

2. Patent Application WO 2010/012470 A1: A system and method for manufacturing a medication (2010).

3. W. Meyer, Farbe und Lack, 112(3), (2006).

4. E.R. Lee, Methods of Generating Monodisperse Microdrops. Microdrop Generation (CRC Press LCC, Florida, USA, 2003) pp 15–32.

5. BD. Glass and A. Haywood, J. Pharm. Pharmaceut. Sci., 9(3), 398–426 (2006).

6. T.J. Nicolson et al., Trends in Pharmacological Sciences, 31(3), 108–114 (2010).

7. FDA, Evaluation of Gender Differences in Clinical Investigations — Information Sheet. Clinical Trial Guidance (1998). http://www.fda.gov/

8. H. Ahmed and N. Shah, American Pharmaceutical Review, 3(3) (2000).

9. S. Yang and J.R.G. Evans, Powder Technology, 178(1), 56–72 (2007).

10. R. Mitchell and D. Edwards, Pharmaceutical Technology Europe, 21(7), 22–24 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here